PanOptica, Inc., is a private, clinical-stage biopharmaceutical company focused on developing a topical eye drop for the treatment of sight-threatening eye diseases caused by abnormal or leaky blood vessels. These neovascular eye diseases include neovascular age-related macular degeneration (wet AMD), the leading cause of blindness in the Western world, and diabetic retinopathy.
